DRADS Capital

DRADS Capital proudly ventured into the sustainable energy sector five years ago with our inaugural investment in Alsym Energy. Since that pivotal moment, our belief in Alsym's mission and technology has only deepened, evidenced by our continued investment through each funding round. Meeting Mukesh Chatter, Alsym’s co-founder and CEO, for the first time was nothing short of inspirational. With a proven track record of entrepreneurial success, including the billion-dollar exit of his previous startup, Mukesh’s vision for Alsym resonated with us immediately. It was clear he possessed the experience and drive necessary to lead such an ambitious project. DRADS was honoured to make our first investment — supporting Alsym's journey from an ambitious concept to the pioneering company it is today. Over the past five years, the team at Alsym, under Mukesh’s leadership, has worked tirelessly to realize their vision and this dedication has brought us to the present moment, where we are thrilled to participate once again in Alsym's latest achievement, a $78 million Series C funding round. This round, led by General Catalyst and Tata Sons Private Limited, with contributions from Thomvest and Thrive Capital, is a testament to the potential impact of Alsym’s innovative battery technology. This latest investment will accelerate Alsym’s mission to revolutionize energy storage with their low-cost, non-flammable battery chemistry, promising a more sustainable and accessible future for all. The company's approach to using less exotic materials and simpler packs not only sets a new benchmark in the industry but significantly undercuts the cost of traditional lithium-ion cells. This advancement is crucial for both the electrification of emerging markets and the transition towards more sustainable energy sources worldwide. Congratulations to Mukesh Chatter and the entire Alsym team on your continued success. Your remarkable work is not just about creating a product but paving the way towards a greener, more equitable world. DRADS Capital is excited to support Alsym as it moves closer to commercializing its groundbreaking technology, ushering in an era of cheaper, more accessible energy storage solutions. Together, let's redefine what's possible in the realm of sustainable energy. https://lnkd.in/gTKNQk6Y https://lnkd.in/g5JezusX Shaun Patel Shamini Ramanujan Archana Nagarajan Divyesh Nagarajan Jose Manuel Martin Aram T. Salzman Kripa Varanasi Rahul Mukherjee #SustainableEnergy #CleanTech #Innovation #BatteryTechnology #Alsym #EnergyStorage #GreenTech #RenewableEnergy #Investment #StartupSuccess #DradsCapital #ClimateAction #VetureCapital #InvestmentBanking

Today, we celebrate the significant strides The Live Green Co has made over the last two years. Since DRADS Capital spearheaded our Pre-Series A investment round, we’ve seen transformative growth and innovation. Our journey has been marked by the development of groundbreaking Active Functional Ingredients (AFIs) and Functional Foods, alongside pivotal commercial partnerships with leading industry players. A standout achievement is our breakthrough in replicating Structured Triglycerides found in human milk through advanced Precision Fermentation techniques. Human milk, primarily composed of triacylglycerols (TAGs) — which constitute 98% of its total fat content — is vital for infants, providing essential energy and fatty acids crucial for their development, particularly in brain and language skills. Despite the critical role of breastfeeding, approximately 60% of infants globally do not benefit from it completely due to various challenges. The industry's current solution relies heavily on vegetable oils, which unfortunately misaligns with the natural structure found in human breast milk, particularly concerning the positioning of the vital fatty acid, palmitic acid. To bridge this gap, Live Green's innovation leverages yeast engineering to produce a specific fat molecule that closely mimics the nutritional profile of human breast milk, offering a superior alternative to traditional infant formula fats. Our Precision Fermentation process yields structured triglycerides (OPO), promising a significant leap forward in infant nutrition by eliminating the reliance on less suitable vegetable oils. Our commitment to excellence is further demonstrated by our rigorous quality and safety protocols, including a self-affirmed GRAS status confirmed through independent lab analysis. We're also advancing in developing proprietary bioprocessing strategies, aiming to enhance the yield and sustainability of our production processes, ultimately making cleaner, more affordable, and sustainable food systems a reality. At Live Green, under the leadership of Sasikanth Chemalamudi, our dedication to researching and developing clean, functional foods using proprietary technology is unwavering. With the support of DRADS Capital, we're excited to continue driving the global shift towards sustainable food systems, marking a new era in health and nutrition for all. #sustainability #precisionfermentation #health #healthandwellness #plantonly #technology #science #ai #biotechnology #innovation Archana Nagarajan Divyesh Nagarajan Shamini Ramanujan Shaun Patel Priyanka Srinivas Kenneth Chan Masamichi Ujiie Leonard Ariff Abdul Shatar Ludwig Douglas Amer Baig Wan Jeffery Majid Wu kong Chek

Last week, I had the profound privilege of visiting the headquarters of ROKIT Healthcare in Seoul. Reflecting on our journey over the past three years since DRADS Capital’s round-leading investment, I am filled with immense pride in what we have accomplished together. Since this investment, ROKIT Healthcare has achieved a plethora of noteworthy milestones, including securing FDA and European approvals, successfully completing clinical trials, and achieving commercialization in over 30 countries. These accomplishments speak volumes about ROKIT’s commitment to innovation and excellence in the medical devices sector. A particular highlight of ROKIT’s achievements is the 2A rating awarded by the KOSDAQ Technical Evaluation Assessment Agency, a testament to their technological innovation and market potential. Moreover, the CE approvals for commercialization in European countries underscore the quality and safety of their products. The European Medical Agency's classification of their device as a "class IIa" medical device reflects rigorous evaluation and compliance with the highest standards. Central to ROKIT's achievements is the visionary leadership of Chairman SeokHwan. You. His foresight and dedication have not only cultivated a culture of innovation but also steered the company through groundbreaking advancements, demonstrating the transformative impact of exceptional leadership in the healthcare industry. As we look forward, ROKIT’s trajectory is a compelling example of how innovative technology can address complex healthcare challenges worldwide. DRADS Capital is proud to be part of this journey — contributing to a future where healthcare is enhanced by technology. JEEHEE KIM, PH.D, Kenneth Chan, Aram T. Salzman, Shaun Patel, Shamini Ramanujan, Archana Nagarajan, Divyesh Nagarajan, #biotechnology, #lifesciences, #genomics, #antiaging, #regeneration, #KOSDAQ, #Korean, #government, #Seoul, #Harvard, #regeneration, #kidney, #healthcare

Wishing friends, family, business partners, and all those celebrating a very Happy Diwali!

Wishing friends, family, business partners, and all those celebrating a very Happy Diwali!